Dopamine D1A receptor function in a rodent model of tardive dyskinesia

Neuroscience ◽  
2000 ◽  
Vol 101 (3) ◽  
pp. 629-635 ◽  
Author(s):  
J.M Van Kampen ◽  
A.J Stoessl
Keyword(s):  
Tardive Dyskinesia ◽  
Rodent Model ◽  
Receptor Function

The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia

1993 ◽  
Vol 8 (4) ◽  
pp. 445-452 ◽  
Author(s):  
A. Jon Stoessl ◽  
Elizabeth Polanski ◽  
Hanna Frydryszak
Keyword(s):  
Tardive Dyskinesia ◽  
Rodent Model ◽  
Opiate Antagonist

Clozapine and D1/D2 Antagonism in Extrapyramidal Functions

1992 ◽  
Vol 160 (S17) ◽  
pp. 34-37 ◽  
Author(s):  
Jes Gerlach ◽  
Lars Hansen
Keyword(s):  
Side Effects ◽  
Tardive Dyskinesia ◽  
Side Effect ◽  
Receptor Blockade ◽  
Biochemical Profile ◽  
Extrapyramidal Side Effects ◽  
Receptor Function ◽  
Extrapyramidal Side Effect ◽  
Extrapyramidal Syndromes

One of the main advantages of clozapine is that it rarely produces extrapyramidal syndromes and tardive dyskinesia. This advantage is linked to the atypical biochemical profile of clozapine, especially its combined and low blockade of D1 and D2 receptors. The level of D2 receptor blockade is too low to induce extrapyramidal side-effects, and D1 antagonists have a lower extrapyramidal side-effect potential than traditional D2 neuroleptics, especially with respect to dystonia. The combined and balanced D1/D2 receptor blockade may prevent the development of a dysbalance between D1/D2 receptor function (in favour of D1) which otherwise might lead to tardive dyskinesia.

scholarly journals Multidose Risperidone Treatment Evaluated in a Rodent Model of Tardive Dyskinesia

2005 ◽  
Vol 31 (9) ◽  
pp. 1864-1868 ◽  
Author(s):  
Xue-Min Gao ◽  
Thomas Cooper ◽  
Raymond F Suckow ◽  
Carol A Tamminga
Keyword(s):  
Tardive Dyskinesia ◽  
Rodent Model ◽  
Risperidone Treatment
Sign in / Sign up

Export Citation Format

Share Document